全文获取类型
收费全文 | 51516篇 |
免费 | 3654篇 |
国内免费 | 1689篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 742篇 |
妇产科学 | 94篇 |
基础医学 | 2152篇 |
口腔科学 | 63篇 |
临床医学 | 9001篇 |
内科学 | 21978篇 |
皮肤病学 | 51篇 |
神经病学 | 578篇 |
特种医学 | 2139篇 |
外科学 | 3181篇 |
综合类 | 9383篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 1171篇 |
眼科学 | 29篇 |
药学 | 4197篇 |
34篇 | |
中国医学 | 1936篇 |
肿瘤学 | 110篇 |
出版年
2024年 | 98篇 |
2023年 | 757篇 |
2022年 | 1285篇 |
2021年 | 2018篇 |
2020年 | 1912篇 |
2019年 | 1889篇 |
2018年 | 1768篇 |
2017年 | 1326篇 |
2016年 | 1322篇 |
2015年 | 1468篇 |
2014年 | 3290篇 |
2013年 | 3132篇 |
2012年 | 2393篇 |
2011年 | 2839篇 |
2010年 | 2357篇 |
2009年 | 2220篇 |
2008年 | 2417篇 |
2007年 | 2572篇 |
2006年 | 2374篇 |
2005年 | 2107篇 |
2004年 | 1741篇 |
2003年 | 1571篇 |
2002年 | 1396篇 |
2001年 | 1450篇 |
2000年 | 1198篇 |
1999年 | 1132篇 |
1998年 | 1007篇 |
1997年 | 1012篇 |
1996年 | 784篇 |
1995年 | 714篇 |
1994年 | 694篇 |
1993年 | 554篇 |
1992年 | 516篇 |
1991年 | 471篇 |
1990年 | 404篇 |
1989年 | 315篇 |
1988年 | 328篇 |
1987年 | 315篇 |
1986年 | 269篇 |
1985年 | 284篇 |
1984年 | 271篇 |
1983年 | 175篇 |
1982年 | 180篇 |
1981年 | 137篇 |
1980年 | 105篇 |
1979年 | 82篇 |
1978年 | 69篇 |
1977年 | 42篇 |
1976年 | 31篇 |
1975年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
强心通脉灵对大鼠急性心肌梗死后心室重构的影响 总被引:1,自引:0,他引:1
目的探讨强心通脉灵对急性心肌梗死(AMI)大鼠心室重构(VR)的干预机制。方法选择Wistar大鼠85只,随机分为强心通脉灵大剂量组(QXLmax组)12只、强心通脉灵小剂量组(QXLmin组)14只、卡托普利组11只、模型组15只和假手术组13只,采取冠状动脉结扎造成AMI模型,术后均予口服给药治疗,模型组及假手术组予以相应的生理盐水。4周后处死,放射免疫法测血浆血管紧张素Ⅱ(AngⅡ)和超氧化物歧化酶(SOD)含量,计算左心室质量指数,光镜下观察心尖组织病理形态学改变,采用ABC染色测TGF-β1的表达量。结果模型组及各给药组AngⅡ水平较高,各给药组较模型组有下降趋势,其中QXLmax组较卡托普利组及QXLmin组更低。模型组及各给药组SOD水平较假手术组降低,QXLmax组及QXLmin组较模型组有升高趋势,左心室质量指数模型组较假手术组显著升高,各给药组较假手术组有升高趋势,QXLmax组较QXLmin组及卡托普利组低。卡托普利组及QXLmin组健存心肌细胞周围胶原组织明显减少,QXLmax组病理改变最轻,偶有少量胶原纤维增生。TGF-β1表达QXLmax组较QXLmin组及卡托普利组低(P<0.01)。结论强心通脉灵可降低AMI后大鼠血浆AngⅡ水平,增加SOD活性,降低左心室质量指数及心肌组织TGF-β1表达,从而平稳AMI后VR的进程。 相似文献
42.
BEATA WOAKOWSKA-KAPLON GRZEGORZ OPOLSKI† 《Pacing and clinical electrophysiology : PACE》2005,28(S1):S110-S114
Atrial fibrillation (AF) may be associated with activation of atrial natriuretic peptide (ANP). The exact trigger for the release of ANP is still being debated. Atrial volume, pressure, and wall stretch are considered to be the main determinants of ANP activation. The aim of the study was to evaluate plasma ANP concentrations in patients with persistent AF and to analyze the echocardiographic determinants of ANP concentration in this group. The study population included 67 patients, 59 ± 7 years of age, with a median AF duration of 5.5 months (range 0.1–12). The relationship between plasma ANP concentrations and echocardiographic left atrial (LA) diameter and volume, and left ventricular (LV) diameter and ejection fraction (EF) was analyzed by logistic regression analysis. The median baseline plasma ANP concentration was 63 pg/mL (range 21–126) in the study group versus 34 pg/mL (range 16–73) in a control group. The mean left antero-posterior atrial dimension, LA volume, LV enddiastolic diameter, and LVEF were 48 mm, 104 mL, 52 mm, and 54%, respectively. A significant linear positive correlation was found between plasma ANP concentration and maximal LA volume (r = 0.62, P < 0.01). A negative correlation was found between LVEF and plasma ANP concentration (r =−0.42, P = 0.01). However, by multivariate regression analysis, no echocardiographic parameter was an independent predictor of plasma ANP concentration. Plasma ANP concentrations were independent of echocardiographic measurements of LA size or LV size and function in patients with persistent AF. 相似文献
43.
Leslee J. Shaw Romalisa Miranda-Peats Piotr Slomka John Friedman Sean W. Hayes Daniel S. Berman Gary V. Heller Marcin Dada William E. Boden Paul Casperson Robert A. O’Rourke Ronald Schwartz William S. Weintraub David J. Maron Spencer King Koon Teo Pamela Hartigan 《Journal of nuclear cardiology》2006,13(5):685-698
Background Stress gated myocardial perfusion single photon emission computed tomography (gSPECT) is increasingly used before and after
intercurrent therapeutic intervention and is the basis for ongoing evaluation in the Department of Veterans Affairs clinical
outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial.
Methods and Results The COURAGE trial is a North American multicenter randomized clinical trial that enrolled 2287 patients to aggressive medical
therapy vs percutaneous coronary intervention plus aggressive medical therapy. Three COURAGE nuclear substudies have been
designed. The goals of substudy 0 are to examine the diagnostic accuracy of the extent and severity of inducible ischemia
at baseline in COURAGE patients compared with patient symptoms and quantitative coronary angiography and to explore the relationship
between inducible ischemia and the benefit from revascularization when added to medical therapy. Substudy 1 will correlate
the extent and severity of provocative ischemia with the frequency, quality, and instability of recurrent symptoms in postcatheterization
patients. Substudy 2 (n _ 300) will examine the usefulness of sequential gSPECT monitoring 6 to 18 months after therapeutic
intervention. Together, these nuclear substudies will evaluate the role of gSPECT to determine the effectiveness of aggressive
risk-factor modifications, lifestyle interventions, and anti-ischemic medical therapies with or without revascularization
in reducing patients’ ischemic burdens.
Conclusions The unfolding of evidence on the application of gSPECT in trials such as COURAGE defines a new era for nuclear cardiology.
We hope the evidence that emerges from the COURAGE trial will further establish the role of nuclear imaging in the evidence-based
management of patients with stable coronary disease.
The COURAGE trial was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research
and Development in collaboration with the Canadian Institutes of Health Research. Unrestricted research grants were obtained
from Merck & Co; Pfizer Pharmaceuticals; Bristol-Myers Squibb Medical Imaging; Astellas Pharma; Kos Pharmaceuticals; Data
Scope; Astra Zeneca Pharmaceuticals; Astra-Zeneca-Canada; Schering-Plough Coorporation, Ltd; Sanofi-Aventis, Inc; First Horizon;
and GE Healthcare. All industrial funding for this trial was directed through the Department of Veterans Affairs. Additional
funding for this substudy was provided by grants to the Department of Veterans Affairs and Canadian Institutes of Health Research
from Astellas Pharma and Bristol-Myers-Squibb Medical Imaging. 相似文献
44.
45.
Pleomorphic Ventricular Tachycardia: Demonstration of Conduction Reversal Within the Reentry Circuit
KARL-HEINZ KUCK MICHAEL SCHLÜTER KLAUS-PETER KUNZE MANFRED GEIGER 《Pacing and clinical electrophysiology : PACE》1989,12(7):1055-1064
A case is presented of a patient with incessant venfricular tacbycardia of left bundle branch block morphology. Endocardial mapping revealed the site of earliest activation during tachycardia to be the proximal right ventricular septum. Pacing at this site elicited the clinical tachycardia, whereas pacing at the proximal left ventricular septum induced a right bundle branch block morphology identical to that of a previously recorded spontaneous ventricuiar tachycardia. Electrophysiological evidence is given that both types of tachycardia originate from a single reentry circuit located in the proximal ventricular septum in which the reentrant wavefront may travel either orthodromically (during spontaneous tachycardia and right ventricular pacing) or antidromically (during left ventricular pacing). 相似文献
46.
目的我们应用平衡法门控心血池显像技术对不同Killip分级的前壁心肌梗死患者进行左室总体和局部收缩和舒张功能参数的对比分析。方法对照组15例(G0),前壁心肌梗死KillipⅠ级17例(G1),前壁心肌梗死KillipⅡⅢ级12例(G2)。利用平衡法门控心血池显像技术评价3组的左室总体和局部的收缩与舒张功能。结果①左室整体收缩功能,在LVEF,ESC 2个参数中,G1比G0有显著差异(P<0.05),G2分别比G1和G0有显著差异(P<0.05)。在PER、1/3EF、1/3ER 3个参数中,G2分别比G1和G0显著下降(P<0.05)。②左室总体舒张功能,在PFR、1/3FF、1/3FR、EDC中,G1比G0有显著差异(P<0.05),G2分别比G1和G0有显著差异(P<0.05)。③左室局部收缩功能,在以LVREF为参数时,G1在4个节段比G0显著差异(P<0.05),G2在所有6个节段中比G1和G0均显著下降(P<0.05)。④左室局部舒张功能,在以LVR1/3FF为参数时,G1在4个节段比G0显著下降(P<0.05),G2在所有6个节段比G0和G1均显著下降(P<0.05)。结论前壁心肌梗死后出现心功能受损或心力衰竭的主要原因为左室重构。 相似文献
47.
48.
49.
Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS 总被引:2,自引:0,他引:2
I. FUCHS† M. FROSSARD† A. SPIEL E. RIEDMÜLLER† A. N. LAGGNER† B. JILMA 《Journal of thrombosis and haemostasis》2006,4(12):2547-2552
BACKGROUND: Platelet hyperfunction contributes to acute coronary syndromes (ACS). Thus, we hypothesized that platelet function under high shear stress predicts recurrent ACS during long-term follow-up of ACS patients. PATIENTS AND METHODS: Consecutive ACS patients (n = 208) were prospectively followed-up for an average of 28 months. Platelet function was measured with the platelet function analyzer (PFA-100; Dade Behring, Marburg, Germany) at baseline for collagen/adenosine diphosphate closure times (CADP-CT) and for collagen/epinephrine closure times (CEPI-CT) after infusion of a uniform dose of 250 mg aspirin. RESULTS: Of the conventional risk factors, only the prevalence of diabetes was higher in ACS patients with re-events. However, use of clopidogrel and use of beta blockers were also slightly lower in patients with re-events (P < 0.05). The unadjusted risk hazard ratio (HR) for re-events was 3.3 [95% confidence interval (95% CI): 1.4-7.4; P = 0.005] in those patients with the shortest CADP-CT values (lowest quartile). Similarly, the risk was 2.0-fold higher (95% CI: 1.1-3.6; P = 0.02) in ACS patients with CEPI-CT < 300 s as compared with CEPI-CT >or = 300 s. Inclusion of diabetes, clopidogrel and beta blockers in a multivariate Cox regression model enhanced the predictive value of CEPI-CT (HR: 2.7). Inclusion of von Willebrand factor levels did not alter the HR for recurrent ACS (HR: 2.1; 95% CI: 1.1-5.2; P = 0.03) for CEPI-CT < 300 s, but reduced the HR for CADP-CT (HR: 2.8, 95% CI: 0.8-9.8; P = 0.11). CONCLUSION: Shortened CT values reflect biologically relevant platelet hyperfunction in patients with ACS because they predict recurrent ACS. 相似文献
50.
黄震华 《中国新药与临床杂志》2005,24(10):829-832
心肌钠钙交换在调节心肌细胞内外钠、钙平衡中发挥重要作用。钠钙交换分为前向型和逆向型2种。在心力衰竭、心肌缺血、心肌再灌注等病理情况下,通过钠钙交换器的离子交换可产生致心律失常性的一过性内向电子流,引起延迟后除极和非折返激动型的室性心动过速。钠钙交换器抑制药在预防这些病理情况下的心律失常具有潜在的作用。 相似文献